Literature DB >> 12209135

Nf-kappa B, chemokine gene transcription and tumour growth.

Ann Richmond1.   

Abstract

The constitutive expression of angiogenic and tumorigenic chemokines by tumour cells facilitates the growth of tumours. The transcription of these angiogenic and tumorigenic chemokine genes is modulated, in part, by the nuclear factor-kappa B (NF-kappa B) family of transcription factors. In some tumours, there is constitutive activation of the kinases that modulate the activity of inhibitor of NF-kappa B (I kappa B) kinase (IKK), which leads to the constitutive activation of members of the NF-kappa B family. This activation of NF-kappa B is associated with the dysregulation of transcription of genes that encode cytokines, chemokines, adhesion factors and inhibitors of apoptosis. In this review, I discuss the factors that lie upstream of the NF-kappa B cascade that are activated during tumorigenesis and the role of the putative NF-kappa B enhanceosome in constitutive chemokine gene transcription during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209135      PMCID: PMC2668257          DOI: 10.1038/nri887

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  119 in total

Review 1.  Multiple chemotactic factors: fine control or redundancy?

Authors:  M N Devalaraja; A Richmond
Journal:  Trends Pharmacol Sci       Date:  1999-04       Impact factor: 14.819

2.  Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells.

Authors:  J Anrather; V Csizmadia; M P Soares; H Winkler
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways.

Authors:  J L Norris; A S Baldwin
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

4.  A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation.

Authors:  P O Hassa; M O Hottiger
Journal:  Biol Chem       Date:  1999 Jul-Aug       Impact factor: 3.915

5.  Protein kinase C-dependent activation of NF-kappaB in enterocytes is independent of IkappaB degradation.

Authors:  L Wilson; C Szabó; A L Salzman
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Identification of PTEN mutations in metastatic melanoma specimens.

Authors:  J T Celebi; I Shendrik; D N Silvers; M Peacocke
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

7.  Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity.

Authors:  S Huang; A DeGuzman; C D Bucana; I J Fidler
Journal:  Cytokines Cell Mol Ther       Date:  2000-03

8.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.

Authors:  H Sakurai; H Chiba; H Miyoshi; T Sugita; W Toriumi
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

9.  Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness.

Authors:  M Kunz; A Hartmann; E Flory; A Toksoy; D Koczan; H J Thiesen; N Mukaida; M Neumann; U R Rapp; E B Bröcker; R Gillitzer
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

10.  The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase.

Authors:  O Coqueret; G Bérubé; A Nepveu
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

View more
  179 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

3.  Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells.

Authors:  Ming Yu; Jason Yeh; Carter Van Waes
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

Review 4.  Subversion of innate and adaptive immune responses by Toxoplasma gondii.

Authors:  Christine Lang; Uwe Gross; Carsten G K Lüder
Journal:  Parasitol Res       Date:  2006-10-06       Impact factor: 2.289

5.  Human cytomegalovirus immediate-early 2 protein IE86 blocks virus-induced chemokine expression.

Authors:  R Travis Taylor; Wade A Bresnahan
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

7.  Visualization of AP-1 NF-kappaB ternary complexes in living cells by using a BiFC-based FRET.

Authors:  Y John Shyu; Christopher D Suarez; Chang-Deng Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

Review 8.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

9.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 10.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.